Biocon and Amylin Pharmaceuticals (Amylin) have entered into an exclusive agreement to jointly develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes.
Reportedly, Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin’s “phybrid” technology.
Under the terms of the agreement, Amylin will provide expertise in peptide hormone development, particularly in the area of phybrid technology, as well as metabolic disease therapeutics.
However, Biocon will utilize its expertise in recombinant microbial expression to manufacture the compound and also leverage its experience in pre-clinical and clinical development of diabetes products.
Daniel Bradbury, president and CEO of Amylin, said: “This program could unleash the potential of cutting-edge peptide science to transform the lives of patients with diabetes. We are pleased to work with Biocon and look forward to collaborating with them on this exciting program.”